|
1
|
Huang K, Bai Z, Bian D, Yang P, Li X and
Liu Y: Diagnostic accuracy of contrast-enhanced ultrasonography in
papillary thyroid microcarcinoma stratified by size. Ultrasound Med
Biol. 46:269–274. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Chen AY, Jemal A and Ward EM: Increasing
incidence of differentiated thyroid cancer in the United States,
1988-2005. Cancer. 115:3801–3807. 2009.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Davies L and Welch HG: Increasing
incidence of thyroid cancer in the United States, 1973-2002. JAMA.
295:2164–2167. 2006.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Xu YH, Song HJ, Qiu ZL and Luo QY: Brain
metastases with exceptional features from papillary thyroid
carcinoma: Report of three cases. Hell J Nucl Med. 14:56–59.
2011.PubMed/NCBI
|
|
5
|
Varsavsky M, Cortés Berdonces M, Alonso G,
García Martín A and Muñoz Torres M: Metastatic adenopathy from a
thyroid microcarcinoma: Final diagnosis of a presumed
paraganglioma. Endocrinol Nutr. 58:143–144. 2011.(In Spanish).
PubMed/NCBI View Article : Google Scholar
|
|
6
|
Xing M, Westra WH, Tufano RP, Cohen Y,
Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, et
al: BRAF mutation predicts a poorer clinical prognosis for
papillary thyroid cancer. J Clin Endocrinol Metab. 90:6373–6379.
2005.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kim SW, Lee JI, Kim JW, Ki CS, Oh YL, Choi
YL, Shin JH, Kim HK, Jang HW and Chung JH: BRAFV600E mutation
analysis in fine-needle aspiration cytology specimens for
evaluation of thyroid nodule: A large series in a
BRAFV600E-prevalent population. J Clin Endocrinol Metab.
95:3693–3700. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Min HS, Lee C and Jung KC: Correlation of
immunohistochemical markers and BRAF mutation status with
histological variants of papillary thyroid carcinoma in the Korean
population. J Korean Med Sci. 28:534–541. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kwak JY, Kim EK, Chung WY, Moon HJ, Kim MJ
and Choi JR: Association of BRAFV600E mutation with poor clinical
prognostic factors and US features in Korean patients with
papillary thyroid microcarcinoma. Radiology. 253:854–860.
2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Millington GW: Mutations of the BRAF gene
in human cancer, by Davies et al. (Nature 417: 949-954,
2002). Clin Exp Dermatol. 38:222–223. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
DeLuca AM, Srinivas A and Alani RM: BRAF
kinase in melanoma development and progression. Expert Rev Mol Med.
10(e6)2008.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Liu Z, Lv T, Xie C and Di Z: BRAF V600E
gene mutation is associated with bilateral malignancy of papillary
thyroid cancer. Am J Med Sci. 356:130–134. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kebebew E, Weng J, Bauer J, Ranvier G,
Clark OH, Duh QY, Shibru D, Bastian B and Griffin A: The prevalence
and prognostic value of BRAF mutation in thyroid cancer. Ann Surg.
246:466–471. 2007.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK,
Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, et al: The association of
the BRAF(V600E) mutation with prognostic factors and poor clinical
outcome in papillary thyroid cancer: A meta-analysis. Cancer.
118:1764–1773. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gschwandtner E, Klatte T, Swietek N, Bures
C, Kober F, Ott J, Schultheis A, Neuhold N and Hermann M: Increase
of papillary thyroid microcarcinoma and a plea for restrictive
treatment: A retrospective study of 1,391 prospective documented
patients. Surgery. 159:503–511. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yi D, Song P, Huang T, Tang X and Sang J:
A meta-analysis on the effect of operation modes on the recurrence
of papillary thyroid microcarcinoma. Oncotarget. 8:7148–7156.
2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sobin LH: Histological typing of thyroid
tumours. Histopathology. 16(513)1990.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yoon JH, Lee HS, Kim EK, Youk JH, Kim HG,
Moon HJ and Kwak JY: Short-term follow-up us leads to higher
false-positive results without detection of structural recurrences
in PTMC. Medicine (Baltimore). 95(e2435)2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Huang XP, Ye TT, Zhang L, Liu RF, Lai XJ,
Wang L, Yang M, Zhang B, Li XY, Liu ZW, et al: Sonographic features
of papillary thyroid microcarcinoma predicting high-volume central
neck lymph node metastasis. Surg Oncol. 27:172–176. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ferris RL, Baloch Z, Bernet V, Chen A,
Fahey TJ III, Ganly I, Hodak SP, Kebebew E, Patel KN, Shaha A, et
al: American thyroid association statement on surgical application
of molecular profiling for thyroid nodules: Current impact on
perioperative decision making. Thyroid. 25:760–768. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Hay ID, Hutchinson ME, Gonzalez-Losada T,
McIver B, Reinalda ME, Grant CS, Thompson GB, Sebo TJ and Goellner
JR: Papillary thyroid microcarcinoma: A study of 900 cases observed
in a 60-year period. Surgery. 144:980–988. 2008.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Baudin E, Travagli JP, Ropers J, Mancusi
F, Bruno-Bossio G, Caillou B, Cailleux AF, Lumbroso JD, Parmentier
C and Schlumberger M: Microcarcinoma of the thyroid gland: The
Gustave-Roussy Institute experience. Cancer. 83:553–559.
1998.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Pacini F, Molinaro E, Castagna MG, Agate
L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L and Pinchera
A: Recombinant human thyrotropin-stimulated serum thyroglobulin
combined with neck ultrasonography has the highest sensitivity in
monitoring differentiated thyroid carcinoma. J Clin Endocrinol
Metab. 88:3668–3673. 2003.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Torlontano M, Attard M, Crocetti U, Tumino
S, Bruno R, Costante G, D'Azzò G, Meringolo D, Ferretti E, Sacco R,
et al: Follow-up of low risk patients with papillary thyroid
cancer: Role of neck ultrasonography in detecting lymph node
metastases. J Clin Endocrinol Metab. 89:3402–3407. 2004.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Tuttle RM, Tala H, Shah J, Leboeuf R,
Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA and Shaha A:
Estimating risk of recurrence in differentiated thyroid cancer
after total thyroidectomy and radioactive iodine remnant ablation:
Using response to therapy variables to modify the initial risk
estimates predicted by the new American thyroid association staging
system. Thyroid. 20:1341–1349. 2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Leboulleux S, Girard E, Rose M, Travagli
JP, Sabbah N, Caillou B, Hartl DM, Lassau N, Baudin E and
Schlumberger M: Ultrasound criteria of malignancy for cervical
lymph nodes in patients followed up for differentiated thyroid
cancer. J Clin Endocrinol Metab. 92:3590–3594. 2007.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Pelttari H, Laitinen K, Schalin-Jäntti C
and Välimäki MJ: Long-term outcome of 495 TNM stage I or II
patients with differentiated thyroid carcinoma followed up with
neck ultrasonography and thyroglobulin measurements on T4
treatment. Clin Endocrinol (Oxf). 69:323–331. 2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Yoon JH, Kim JY, Moon HJ, Youk JH, Son EJ,
Kim EK, Han KH and Kwak JY: Contribution of computed tomography to
ultrasound in predicting lateral lymph node metastasis in patients
with papillary thyroid carcinoma. Ann Surg Oncol. 18:1734–1741.
2001.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Nixon IJ, Ganly I, Patel SG, Palmer FL,
Whitcher MM, Tuttle RM, Shaha A and Shah JP: Thyroid lobectomy for
treatment of well differentiated intrathyroid malignancy. Surgery.
151:571–579. 2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Durante C, Attard M, Torlontano M, Ronga
G, Monzani F, Costante G, Ferdeghini M, Tumino S, Meringolo D,
Bruno R, et al: Identification and optimal postsurgical follow-up
of patients with very low-risk papillary thyroid microcarcinomas. J
Clin Endocrinol Metab. 95:4882–4888. 2010.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kim MH, Bae JS, Lim DJ, Lee H, Jeon SR,
Park GS and Jung CK: Quantification of BRAF V600E alleles predicts
papillary thyroid cancer progression. Endocr Relat Cancer.
21:891–902. 2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Shin DY, Kim KJ, Chang S, Kim H, Hwang S,
Kim W, Bae J, Park S, Kang SW, Chung WY and Lee EJ: Follicular
variant of papillary thyroid carcinoma with B-type Raf(V600E)
showing higher frequency of suspicious sonographic features and
multifocality. Head Neck. 37:1590–1595. 2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wada N, Duh QY, Sugino K, Iwasaki H,
Kameyama K, Mimura T, Ito K, Takami H and Takanashi Y: Lymph node
metastasis from 259 papillary thyroid microcarcinomas: Frequency,
pattern of occurrence and recurrence, and optimal strategy for neck
dissection. Ann Surg. 237:399–407. 2003.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Li F, Chen G, Sheng C, Gusdon AM, Huang Y,
Lv Z, Xu H, Xing M and Qu S: BRAFV600E mutation in papillary
thyroid microcarcinoma: A meta-analysis. Endocr Relat Cancer.
22:159–168. 2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Guo L, Ma YQ, Yao Y, Wu M, Deng ZH, Zhu
FW, Luo YK and Tang J: Role of ultrasonographic features and
quantified BRAFV600E mutation in lymph node metastasis in Chinese
patients with papillary thyroid carcinoma. Sci Rep.
9(75)2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Xing M, Alzahrani AS, Carson KA, Viola D,
Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, et al:
Association between BRAF V600E mutation and mortality in patients
with papillary thyroid cancer. JAMA. 309:1493–1501. 2013.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ
and Qu JM: The BRAF mutation is predictive of aggressive
clinicopathological characteristics in papillary thyroid
microcarcinoma. Ann Surg Oncol. 17:3294–3300. 2010.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Miccoli P and Basolo F: BRAF mutation
status in papillary thyroid carcinoma: Significance for surgical
strategy. Langenbecks Arch Surg. 399:225–228. 2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Durante C, Puxeddu E, Ferretti E, Morisi
R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A,
et al: BRAF mutations in papillary thyroid carcinomas inhibit genes
involved in iodine metabolism. J Clin Endocrinol Metab.
92:2840–2843. 2007.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Zafon C, Baena JA, Castellví J, Obiols G,
Monroy G and Mesa J: Differences in the form of presentation
between papillary microcarcinomas and papillary carcinomas of
larger size. J Thyroid Res. 2011(639156)2010.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Huang K, Gao N, Zhai Q, Bian D, Wang D and
Wang X: The anteroposterior diameter of nodules in the risk
assessment of papillary thyroid microcarcinoma. Medicine
(Baltimore). 97(e9712)2018.PubMed/NCBI View Article : Google Scholar
|
